Induction Treatment for HIV-Associated Cryptococcal Meningitis: Where Have We Been and Where Are We Going?
Microorganisms · 08.04.2025 · 13 (4) · 847
DOI: 10.3390/microorganisms13040847 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 08.04.2025. Verfasst von Dominique Milsap und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Neurological Disorders.
Abstract (Originalsprache)
Cryptococcal meningitis remains a leading cause of morbidity and mortality among individuals with HIV/AIDS, particularly in resource-limited settings. Treatment begins with induction therapy followed by consolidation and maintenance. Evidence related to induction therapy has evolved significantly over the past decade. Current treatment relies primarily on three antifungal agents: amphotericin B, flucytosine, and fluconazole, each with distinct mechanisms of action and limitations. The World Health Organization’s 2022 guidelines for induction therapy recommend a single high dose of liposomal amphotericin B combined with 14 days of flucytosine and fluconazole. The 2010 IDSA guidelines for induction therapy recommend amphotericin B deoxycholate and flucytosine for two weeks. The U.S. CDC/NIH/IDSA/HIVMA joint guidelines and the ECCM/ISHAM/ASM joint guidelines list both options, but the recommendation varies by setting resources (e.g., resource-limited vs. other). The newer treatment approaches (single high-dose liposomal amphotericin B) that are supported by trials such as AMBITION-cryptococcal meningitis have limited adoption in high-resource settings, with recent studies showing that only 14% of North American infectious disease providers have utilized the regimen. Adjunctive medications, such as dexamethasone, tamoxifen, and sertraline, have proven ineffective or harmful in clinical trials. This review underscores the ongoing challenges in cryptococcal meningitis treatment and the need for continued research to improve patient outcomes, tracing the evolution from past monotherapy approaches to current combination strategies while exploring future directions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
- Infectious Diseases Institute, Makerere University, Kampala, Uganda.
- Clinical Epidemiology Unit, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
- School of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
- Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, 420 Delaware Street, SE, MMC 250, Minneapolis, MN 55455, USA.
ORCID-Profile: Enos Kigozi, Nathan C Bahr
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institutes of Neurological Disorders
- Stroke of the U.S. National Institutes of Health
Zitieren
APA
Milsap, D., Okuno, M., Kigozi, E., Mugabi, T., Faizo, S., Bajer, A., Gakuru, J., & Bahr, N. C. (2025). Induction Treatment for HIV-Associated Cryptococcal Meningitis: Where Have We Been and Where Are We Going?. Microorganisms, 13(4), 847. https://doi.org/10.3390/microorganisms13040847
Vancouver
Milsap D, Okuno M, Kigozi E, Mugabi T, Faizo S, Bajer A, et al. Induction Treatment for HIV-Associated Cryptococcal Meningitis: Where Have We Been and Where Are We Going?. Microorganisms. 2025;13(4):847. doi:10.3390/microorganisms13040847
BibTeX
@article{Milsap2025,
author = {Milsap, Dominique and Okuno, Madison and Kigozi, Enos and Mugabi, Timothy and Faizo, Ssekindi and Bajer, Aleksandra and Gakuru, Jane and Bahr, Nathan C},
title = {Induction Treatment for HIV-Associated Cryptococcal Meningitis: Where Have We Been and Where Are We Going?},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {4},
pages = {847},
doi = {10.3390/microorganisms13040847}
}
EUVIMED